Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 5,258 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Autoimmune Disease Clear all
Enrolling by invitation Not applicable Interventional

G7 Dual Mobility With Vivacit-E or Longevity PMCF

NCT05548972
View directory record Official record
Conditions
Hip Osteoarthritis, Rheumatoid Arthritis, Joint Diseases, Avascular Necrosis, Dislocation, Hip, Femoral Neck Fractures, Trochanteric Fractures, Revision Surgeries
Interventions
G7 Dual Mobility with Vivacit-E bearing, G7 Dual Mobility Longevity bearing
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 80 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2037
U.S. locations
6
States / cities
Little Rock, Arkansas • Denver, Colorado • Jersey City, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 21, 2026, 5:21 AM EDT
Not yet recruiting Phase 4 Interventional

Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)

NCT07820995
View directory record Official record
Conditions
IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Interventions
atrasentan
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue

NCT04144257
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
[F-18]PBR06, [C-11]Methylreboxetine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Not applicable Interventional

Virtual Physical Activity for Type 1 Diabetes

NCT05163912
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Virtual home intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
14 Years to 19 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 2 Interventional

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

NCT00718692
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Sym001
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Omaha, Nebraska • Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 21, 2026, 5:21 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS)

NCT03723356
View directory record Official record
Conditions
Multiple Sclerosis, Cognition Disorders
Interventions
Siemens Biograph mMR (molecular MR), fMRI, Diffusion Spectrum Imaging (DSI)
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 21, 2026, 5:21 AM EDT
Active, not recruiting Not applicable Interventional

Recurrent Hypoglycemia in Type 1 Diabetes (Aim 2)

NCT04387422
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Experimental hyperglycemia
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 21, 2026, 5:21 AM EDT
Not listed Phase 3 Interventional

Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics

NCT03535402
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab
Drug
Lead sponsor
Gaylis, Norman B., M.D.
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 21, 2026, 5:21 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Synergistic Effects of AIH and FES in Persons With MS

NCT06413602
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions
Acute Intermittent Hypoxia, Neuromuscular Electrical Stimulation
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Not applicable Interventional Results available

Impact of Custom Assistive and Adaptive Technology in Rehabilitation

NCT03567239
View directory record Official record
Conditions
Disability Physical, Brain Injuries, Stroke, Spinal Cord Injuries, Multiple Sclerosis, Paralysis
Interventions
Using adaptive device.
Device
Lead sponsor
Madonna Rehabilitation Hospital
Other
Eligibility
1 Year to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 21, 2026, 5:21 AM EDT
Completed No phase listed Observational

Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus

NCT00582881
View directory record Official record
Conditions
Mixed Connective Tissue Disease (MCTD), Systemic Lupus Erythematosus (SLE)
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 100 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 21, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional Results available

A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy

NCT03001219
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Anti-TNF-alpha, Methotrexate, Placebo, RO7123520
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Anniston, Alabama • Glendale, Arizona • Mesa, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Not applicable Interventional Results available

Development of a Behavioral Observer for Type 1 Diabetes Mellitus

NCT01434030
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Focus Group
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 21, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional Results available

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

NCT05540665
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Daxdilimab, Placebo (Normal Saline)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • San Dimas, California • Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin

NCT03804983
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hybrid Closed Loop (HCL), Control-IQ with MyTDI
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 18 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 21, 2026, 5:21 AM EDT
Enrolling by invitation No phase listed Observational

Tornier HRS (Humeral Reconstruction System) Study (REVIVE)

NCT05500066
View directory record Official record
Conditions
Rheumatoid Arthritis, Osteoarthritis Shoulder, Fractures Humerus, Avascular Necrosis, Correction of Functional Deformity, Traumatic Arthritis, Revision of Other Devices if Sufficient Bone Stock Remains, Rotator Cuff Tears
Interventions
Tornier HRS (HUMERAL RECONSTRUCTION SYSTEM) shoulder system
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
4
States / cities
Denver, Colorado • Bradenton, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients

NCT01328522
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR153191 (REGN88)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Beverly Hills, California • Ocala, Florida • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 21, 2026, 5:21 AM EDT
Completed No phase listed Observational Results available

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

NCT06418529
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
21,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Islet Transplantation in Type 1 Diabetic Patients

NCT00214253
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Thiazolidinedione
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 21, 2026, 5:21 AM EDT
Withdrawn Phase 4 Interventional

Velcade for Proliferative Lupus Nephritis

NCT01169857
View directory record Official record
Conditions
Lupus Nephritis, Proteinuria, Hematuria
Interventions
Velcade
Drug
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)

NCT01362153
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Golimumab
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Glendale, Arizona • Aventura, Florida • Palm Harbor, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study

NCT02952911
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Smartphone and Smartwatch
Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

A Moderate to Severe Rheumatoid Arthritis Study

NCT01721044
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Baricitinib, cDMARD
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
32
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional

Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus

NCT00501709
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Belatacept and Raptiva
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 21, 2026, 5:21 AM EDT